BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics - Gilde Healthcare

BG MEDICINE Appoints Doug White as Executive Vice President & General Manager, Diagnostics

3. März 2009

Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics.  In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s commercial operations as it advances a broad portfolio of high-value diagnostic tests toward commercial launch.

Mr. White brings more than 24 years of successful experience in the in vitro diagnostic marketplace to BG Medicine, including roles at innovative leading companies such as QIAGEN, Digene, Bayer, Chiron Diagnostics, and Abbott Diagnostics.  Prior to joining BGM, Mr. White served as QIAGEN’s Sr. Vice President of Sales and Marketing for the Americas, and Chair of the Americas Management Council, where among other responsibilities he played a critical role in the successful integration of Digene Corporation following its acquisition.  Mr. White also served as Senior Vice President of Commercial Operations, leading commercial activities in the Americas and Asia Pacific and heading the company’s global product management organization at Digene.

“Doug’s vast experience with leading diagnostics innovators will be a tremendous asset to BG Medicine as we prepare to commercialize important new diagnostics in cardiology and other therapeutic areas,”

said BG Medicine President and CEO Pieter Muntendam.

“The success that Doug achieved in a variety of commercial leadership roles has prepared him well to help BG Medicine effectively develop and penetrate these large, important markets.”

“I am very excited to join BG Medicine at such a critical juncture, as we turn our biomarker discovery abilities into groundbreaking new diagnostic tests,” Mr. White said. “BG Medicine is poised to have a major impact on the improvement in patient care and management of a wide array of diseases, beginning with cardiology.”

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins, and metabolites collected from bodily fluids.

Gilde Healthcare Portfolio Company Big Health Raises $75 Million in Series C Funding

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it has raised $75 million in a Series C funding round, led by new investor SoftBank Vision...
19. Januar 2022

ProVerum raises €30M in Series A funding led by Gilde Healthcare & Lightstone Ventures

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the closing of a €30 million Series A equity financing led...
11. Januar 2022

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens,...
21. Dezember 2021